1-20 of 36
Lawrence A. Leiter
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combination of Multiple Low-Risk Lifestyle Behaviors and Incident Type 2 Diabetes: A Systematic Review and Dose-Response Meta-analysis of Prospective Cohort Studies

Tauseef A. Khan, David Field, Victoria Chen, Suleman Ahmad, Sonia Blanco Mejia, Hana Kahleová, Dario Rahelić, Jordi Salas-Salvadó, Lawrence A. Leiter, Matti Uusitupa, Cyril W.C. Kendall, John L. Sievenpiper
Journal: Diabetes Care
Diabetes Care 2023;46(3):643–656
https://doi.org/10.2337/dc22-1024
Published: 22 February 2023
View article titled, Combination of Multiple Low-Risk Lifestyle Behaviors and Incident Type 2 Diabetes: A Systematic Review and Dose-Response Meta-analysis of Prospective Cohort Studies
Open the PDF for Combination of Multiple Low-Risk Lifestyle Behaviors and Incident Type 2 Diabetes: A Systematic Review and Dose-Response Meta-analysis of Prospective Cohort Studies in another window
Journal Articles

Glycemic Index Versus Wheat Fiber on Arterial Wall Damage in Diabetes: A Randomized Controlled Trial

David J.A. Jenkins, Laura Chiavaroli, Arash Mirrahimi, Sandra Mitchell, Dorothea Faulkner, Sandhya Sahye-Pudaruth, Melanie Paquette, Judy Coveney, Omodele Olowoyeye, Darshna Patel, Sathish Chandra Pichika, Balachandran Bashyam, Tishan Maraj, Chantal Gillett, Russell J. de Souza, Livia S.A. Augustin, Sonia Blanco Mejia, Stephanie K. Nishi, Lawrence A. Leiter, Robert G. Josse, Gail E. McKeown-Eyssen, Alan R. Berger, Philip W. Connelly, Korbua Srichaikul, Cyril W.C. Kendall, John L. Sievenpiper, Alan R. Moody
Journal: Diabetes Care
Diabetes Care 2022;45(12):2862–2870
https://doi.org/10.2337/dc22-1028
Published: 01 December 2022
View article titled, Glycemic Index Versus Wheat Fiber on Arterial Wall Damage in Diabetes: A Randomized Controlled Trial
Open the PDF for Glycemic Index Versus Wheat Fiber on Arterial Wall Damage in Diabetes: A Randomized Controlled Trial in another window
Journal Articles

Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58

Rena Pollack, Itamar Raz, Stephen D. Wiviott, Erica L. Goodrich, Sabina A. Murphy, Ilan Yanuv, Aliza Rozenberg, Ofri Mosenzon, Anna Maria Langkilde, Ingrid A.M. Gause-Nilsson, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Marc S. Sabatine, Avivit Cahn
Journal: Diabetes Care
Diabetes Care 2023;46(1):156–164
https://doi.org/10.2337/dc22-1318
Published: 18 November 2022
View article titled, Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58
Open the PDF for Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58 in another window
Journal Articles

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial

Ofri Mosenzon, Itamar Raz, Stephen D. Wiviott, Meir Schechter, Erica L. Goodrich, Ilan Yanuv, Aliza Rozenberg, Sabina A. Murphy, Thomas A. Zelniker, Anna Maria Langkilde, Ingrid A.M. Gause-Nilsson, Martin Fredriksson, Peter A. Johansson, John P.H. Wilding, Darren K. McGuire, Deepak L. Bhatt, Lawrence A. Leiter, Avivit Cahn, Jamie P. Dwyer, Hiddo J.L. Heerspink, Marc S. Sabatine
Journal: Diabetes Care
Diabetes Care 2022;45(10):2350–2359
https://doi.org/10.2337/dc22-0382
Published: 23 August 2022
View article titled, Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial
Open the PDF for Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial in another window
Journal Articles

Relation of Change or Substitution of Low- and No-Calorie Sweetened Beverages With Cardiometabolic Outcomes: A Systematic Review and Meta-analysis of Prospective Cohort Studies

Jennifer J. Lee, Tauseef A. Khan, Nema McGlynn, Vasanti S. Malik, James O. Hill, Lawrence A. Leiter, Per Bendix Jeppesen, Dario Rahelić, Hana Kahleová, Jordi Salas-Salvadó, Cyril W.C. Kendall, John L. Sievenpiper
Journal: Diabetes Care
Diabetes Care 2022;45(8):1917–1930
https://doi.org/10.2337/dc21-2130
Published: 26 July 2022
View article titled, Relation of Change or Substitution of Low- and No-Calorie Sweetened Beverages With Cardiometabolic Outcomes: A Systematic Review and Meta-analysis of Prospective Cohort Studies
Open the PDF for Relation of Change or Substitution of Low- and No-Calorie Sweetened Beverages With Cardiometabolic Outcomes: A Systematic Review and Meta-analysis of Prospective Cohort Studies in another window
Journal Articles

Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58

Ahmed A. Kolkailah, Stephen D. Wiviott, Itamar Raz, Sabina A. Murphy, Ofri Mosenzon, Deepak L. Bhatt, Lawrence A. Leiter, John P.H. Wilding, Ingrid Gause-Nilsson, Marc S. Sabatine, Darren K. McGuire
Journal: Diabetes Care
Diabetes Care 2022;45(2):e27–e29
https://doi.org/10.2337/dc21-1668
Published: 17 January 2022
View article titled, Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58
Open the PDF for Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58 in another window
Journal Articles

Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58

Avivit Cahn, Stephen D. Wiviott, Ofri Mosenzon, Erica L. Goodrich, Sabina A. Murphy, Ilan Yanuv, Aliza Rozenberg, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Ingrid A.M. Gause-Nilsson, Anna Maria Langkilde, Marc S. Sabatine, Itamar Raz
Journal: Diabetes Care
Diabetes Care 2022;45(4):938–946
https://doi.org/10.2337/dc21-1744
Published: 11 January 2022
View article titled, Association of Baseline HbA<sub>1c</sub> With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
Open the PDF for Association of Baseline HbA<sub>1c</sub> With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58 in another window
Journal Articles

A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes

David D. Berg, Stephen D. Wiviott, Benjamin M. Scirica, Thomas A. Zelniker, Erica L. Goodrich, Petr Jarolim, Ofri Mosenzon, Avivit Cahn, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Per Johanson, Anna Maria Langkilde, Itamar Raz, Eugene Braunwald, Marc S. Sabatine, David A. Morrow
Journal: Diabetes Care
Diabetes Care 2021;44(11):2573–2581
https://doi.org/10.2337/dc21-1170
Published: 17 September 2021
View article titled, A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes
Open the PDF for A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes in another window
Journal Articles

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

Ofri Mosenzon, Stephen D. Wiviott, Hiddo J.L. Heerspink, Jamie P. Dwyer, Avivit Cahn, Erica L. Goodrich, Aliza Rozenberg, Meir Schechter, Ilan Yanuv, Sabina A. Murphy, Thomas A. Zelniker, Ingrid A.M. Gause-Nilsson, Anna Maria Langkilde, Martin Fredriksson, Peter A. Johansson, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Marc S. Sabatine, Itamar Raz
Journal: Diabetes Care
Diabetes Care 2021;44(8):1805–1815
https://doi.org/10.2337/dc21-0076
Published: 11 August 2021
View article titled, The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
Open the PDF for The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58 in another window
Journal Articles

Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58

Avivit Cahn, Itamar Raz, Lawrence A. Leiter, Ofri Mosenzon, Sabina A. Murphy, Erica L. Goodrich, Ilan Yanuv, Aliza Rozenberg, Deepak L. Bhatt, Darren K. McGuire, John P.H. Wilding, Ingrid A.M. Gause-Nilsson, Anna Maria Langkilde, Marc S. Sabatine, Stephen D. Wiviott
Journal: Diabetes Care
Diabetes Care 2021;44(5):1159–1167
https://doi.org/10.2337/dc20-2492
Published: 02 March 2021
View article titled, Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58
Open the PDF for Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58 in another window
Journal Articles

A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes

Matthew C. Riddle, George Bakris, Lawrence Blonde, Andrew J.M. Boulton, David D’Alessio, Linda A. DiMeglio, Linda Gonder-Frederick, Korey K. Hood, Frank B. Hu, Steven E. Kahn, Sanjay Kaul, Lawrence A. Leiter, Robert G. Moses, Stephen S. Rich, Julio Rosenstock, Judith Wylie-Rosett
Journal: Diabetes Care
Diabetes Care 2021;44(1):8–10
https://doi.org/10.2337/dci20-0071
Published: 14 December 2020
View article titled, A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes
Open the PDF for A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes in another window
Journal Articles

Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease

Gregory G. Schwartz, Lawrence A. Leiter, Christie M. Ballantyne, Philip J. Barter, Donald M. Black, David Kallend, Fouzia Laghrissi-Thode, Eran Leitersdorf, John J.V. McMurray, Stephen J. Nicholls, Anders G. Olsson, David Preiss, Prediman K. Shah, Jean-Claude Tardif, John Kittelson
Journal: Diabetes Care
Diabetes Care 2020;43(5):1077–1084
https://doi.org/10.2337/dc19-2204
Published: 06 March 2020
View article titled, Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease
Open the PDF for Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study

Avivit Cahn, Ofri Mosenzon, Stephen D. Wiviott, Aliza Rozenberg, Ilan Yanuv, Erica L. Goodrich, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Ingrid A.M. Gause-Nilsson, Martin Fredriksson, Peter A. Johansson, Anna Maria Langkilde, Marc S. Sabatine, Itamar Raz
Journal: Diabetes Care
Diabetes Care 2020;43(2):468–475
https://doi.org/10.2337/dc19-1476
Published: 16 December 2019
View article titled, Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study
Open the PDF for Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study in another window
Includes: Supplementary data
Journal Articles

The Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors in Overweight/Obese Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Jarvis C. Noronha, Stephanie K. Nishi, Catherine R. Braunstein, Tauseef A. Khan, Sonia Blanco Mejia, Cyril W.C. Kendall, Hana Kahleová, Dario Rahelić, Jordi Salas-Salvadó, Lawrence A. Leiter, John L. Sievenpiper
Journal: Diabetes Care
Diabetes Care 2019;42(5):767–776
https://doi.org/10.2337/dc18-2270
Published: 28 March 2019
View article titled, The Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors in Overweight/Obese Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Open the PDF for The Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors in Overweight/Obese Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials in another window
Includes: Supplementary data
Journal Articles

Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial

Lawrence A. Leiter, Hwee Teoh, David Kallend, R. Scott Wright, Ulf Landmesser, Peter L.J. Wijngaard, John J.P. Kastelein, Kausik K. Ray
Journal: Diabetes Care
Diabetes Care 2019;42(1):173–176
https://doi.org/10.2337/dc18-1491
Published: 28 November 2018
View article titled, Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial
Open the PDF for Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum

William T. Cefalu, Sanjay Kaul, Hertzel C. Gerstein, Rury R. Holman, Bernard Zinman, Jay S. Skyler, Jennifer B. Green, John B. Buse, Silvio E. Inzucchi, Lawrence A. Leiter, Itamar Raz, Julio Rosenstock, Matthew C. Riddle
Journal: Diabetes Care
Diabetes Care 2018;41(1):14–31
https://doi.org/10.2337/dci17-0057
Published: 11 December 2017
View article titled, Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a <em>Diabetes Care</em> Editors’ Expert Forum
Open the PDF for Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a <em>Diabetes Care</em> Editors’ Expert Forum in another window
Includes: Supplementary data
Journal Articles

Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension

William T. Cefalu, Lawrence A. Leiter, Tjerk W.A. de Bruin, Ingrid Gause-Nilsson, Jennifer Sugg, Shamik J. Parikh
Journal: Diabetes Care
Diabetes Care 2015;38(7):1218–1227
https://doi.org/10.2337/dc14-0315
Published: 07 April 2015
View article titled, Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension
Open the PDF for Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial

Lawrence A. Leiter, Hwee Teoh, Eugene Braunwald, Ofri Mosenzon, Avivit Cahn, K.M. Prasanna Kumar, Alena Smahelova, Boaz Hirshberg, Christina Stahre, Robert Frederich, Francois Bonnici, Benjamin M. Scirica, Deepak L. Bhatt, Itamar Raz, for the SAVOR-TIMI 53 Steering Committee and Investigators
Journal: Diabetes Care
Diabetes Care 2015;38(6):1145–1153
https://doi.org/10.2337/dc14-2868
Published: 10 March 2015
View article titled, Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial
Open the PDF for Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial in another window
Includes: Supplementary data
Journal Articles

Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial

Jacob A. Udell, Deepak L. Bhatt, Eugene Braunwald, Matthew A. Cavender, Ofri Mosenzon, Ph. Gabriel Steg, Jaime A. Davidson, Jose C. Nicolau, Ramon Corbalan, Boaz Hirshberg, Robert Frederich, KyungAh Im, Amarachi A. Umez-Eronini, Ping He, Darren K. McGuire, Lawrence A. Leiter, Itamar Raz, Benjamin M. Scirica
Journal: Diabetes Care
Diabetes Care 2015;38(4):696–705
https://doi.org/10.2337/dc14-1850
Published: 31 December 2014
View article titled, Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial
Open the PDF for Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study

Lawrence A. Leiter, Molly C. Carr, Murray Stewart, Angela Jones-Leone, Rhona Scott, Fred Yang, Yehuda Handelsman
Journal: Diabetes Care
Diabetes Care 2014;37(10):2723–2730
https://doi.org/10.2337/dc13-2855
Published: 10 September 2014
View article titled, Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study
Open the PDF for Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study in another window
Includes: Supplementary data